Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Autor: Mads Hald Andersen, Julie Westerlin Kjeldsen, Inge Marie Svane, Cathrine Lund Lorentzen, Eva Ehrnrooth

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)

Background We have previously published initial efficacy of the indoleamine 2,3-dioxygenase (IDO)/anti-programmed death ligand 1 (PD-L1) vaccine in combination with nivolumab in 30 anti-PD-1 therapy naïve patients with metastatic melanoma (cohort A)

Externí odkaz: https://doaj.org/article/22612f1107274f5eb13ace7242cc3a38

IO Biotech names Eva Ehrnrooth, MD, PhD as CMO

Publikováno v: EquityBites (M2). 10/13/2017.

Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab

Autor: Julie W. Kjeldsen, Cathrine L. Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Eva Ehrnrooth, Mads H. Andersen, Inge Marie Svane

Publikováno v: Cancer Research. 82:CT535-CT535

Background: Immunotherapy is an effective treatment for patients with metastatic melanoma. However, immune checkpoint inhibitors (ICI) often induce immune-related adverse events and despite high response rates many patients still progress. Nivolumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef75e7ef4951b06312a3e17e0e43272f
https://doi.org/10.1158/1538-7445.am2022-ct535

Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC)

Autor: Jonathan W. Riess, Paul Shaw, Devraj Srinivasan, Pilar Garrido, Jacqueline Vuky, Marya F. Chaney, Shane O'Neill, Alireza Alavi, Diane Opatt McDowell, Eva Ehrnrooth, Ezra Cohen

Publikováno v: Journal of Clinical Oncology. 40:TPS2699-TPS2699

TPS2699 Background: Immunotherapy has transformed the treatment of NSCLC and other solid tumors, such as SCCHN and UBC. However, even with standard-of-care anti-PD-1/PD-L1 therapies, few patients achieve durable benefit even when PD-L1 is overexpress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::887efffadae1b37f2b30eae91bfed38a
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2699

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Autor: Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, Eva Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen, Inge Marie Svane

Publikováno v: Kjeldsen, J W, Lorentzen, C L, Martinenaite, E, Ellebaek, E, Donia, M, Holmstroem, R B, Klausen, T W, Madsen, C O, Ahmed, S M, Weis-Banke, S E, Holmström, M O, Hendel, H W, Ehrnrooth, E, Zocca, M B, Pedersen, A W, Andersen, M H & Svane, I M 2021, ' A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma ', Nature Medicine, vol. 27, pp. pages2212–2223 . https://doi.org/10.1038/s41591-021-01544-x

Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dd3bba1301f4d5d79e0b554e5fade1b
https://curis.ku.dk/ws/files/314958988/s41591_021_01544_x.pdf